Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study
dc.contributor.author | Koca, Sinan | |
dc.contributor.author | Besiroglu, Mehmet | |
dc.contributor.author | Ozcelik, Melike | |
dc.contributor.author | Karaca, Mustafa | |
dc.contributor.author | Bilici, Mehmet | |
dc.contributor.author | Hacioglu, Bekir | |
dc.contributor.author | Dogu, Gamze G. | |
dc.date.accessioned | 2024-04-24T17:14:40Z | |
dc.date.available | 2024-04-24T17:14:40Z | |
dc.date.issued | 2021 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas. | en_US |
dc.identifier.doi | 10.1177/1078155220924075 | |
dc.identifier.endpage | 546 | en_US |
dc.identifier.issn | 1078-1552 | |
dc.identifier.issn | 1477-092X | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | 32419618 | |
dc.identifier.scopus | 2-s2.0-85084830817 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 541 | en_US |
dc.identifier.uri | https://doi.org/10.1177/1078155220924075 | |
dc.identifier.uri | https://hdl.handle.net/11468/18130 | |
dc.identifier.volume | 27 | en_US |
dc.identifier.wos | WOS:000534051900001 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications Ltd | en_US |
dc.relation.ispartof | Journal of Oncology Pharmacy Practice | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Pazopanib | en_US |
dc.subject | Soft Tissue Sarcoma | en_US |
dc.subject | Targeted Therapy | en_US |
dc.title | Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study | en_US |
dc.title | Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study | |
dc.type | Article | en_US |